Stablepharma Ltd

Dr. Steven Chatfield appointed as Non-Executive Chairman of Bath based company Stablepharma Ltd, following an extensive career in vaccine R&D and Covid19 Pandemic.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

Stablepharma Ltd receives MHRA approval for Phase 1 trial of fridge-free tetanus and diphtheria (Td) vaccine.

Stablepharma Ltd has secured a €2.5 million EIC Accelerator grant, recognizing its pioneering fridge-free pharmaceutical technology.

In this week’s blog, HM Treasury considers ISA changes to enable tax support for growth, a new engineering biology regulatory group gives the UK a strategic edge and a key MHRA webinar on ILAP is upcoming.

Stablepharma are delighted to announce that they have been selected to be part of Innovate UK’s prestigious Scaleup Programme, recognising the company's potential to grow exponentially and scale globally.

Stablepharma and AJ Vaccines have established the primary commercial distribution deal with proposed terms, in relation to the distribution and commercialisation of the SPVX02 (Td) in Europe.

Stablepharma Named Life Sciences Innovation Awards Winner by Leading US News Platform, Fierce Pharma, in the “Biotech Innovation” Category

An interview with BB-NCIPD Ltd (Bul Bio) & Özgür Tuncer, CEO & Executive Director Stablepharma Ltd highlights that the two companies have entered into a partnership to produce the world’s first fridge-free Tetanus diphtheria vaccine.